Lynn Durham

Title: Lynn Durham: Innovator in Autism Research

Introduction

Lynn Durham is a prominent inventor based in Geneva, Switzerland. She has made significant contributions to the field of autism research, particularly through her innovative patents. With a total of 7 patents, her work focuses on diagnosing and treating autism spectrum disorder (ASD).

Latest Patents

One of her latest patents is a biomarker assay for use in monitoring autism. This invention relates to protein kinase A (PKA) for diagnosing ASD phenotype 1 in patients. The method involves measuring PKA levels in a patient's sample, where lower levels compared to age and sex-matched controls indicate the presence of ASD phenotype 1. Additionally, this invention monitors variations in ASD severity by tracking changes in PKA levels over time. It also assesses the efficacy of ASD treatments based on PKA level changes. Another significant patent is a pharmaceutical composition for treating autism, which includes substances that raise intracellular cAMP levels and modulate calcium concentration. This composition aims to provide effective treatment options for patients suffering from ASD phenotype 1.

Career Highlights

Lynn Durham is currently associated with Stalicla S.A., a company dedicated to advancing autism research and treatment. Her work has been instrumental in developing innovative solutions for ASD, showcasing her commitment to improving patient outcomes.

Collaborations

Lynn collaborates with notable professionals in her field, including Stéphane Baudouin and Jean-Marc Hyvelin. These partnerships enhance her research and contribute to the development of effective treatments for autism.

Conclusion

Lynn Durham's contributions to autism research through her patents and collaborations highlight her role as a leading inventor in this critical field. Her innovative approaches aim to improve the lives of individuals affected by autism spectrum disorder.